Literature DB >> 24966969

High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.

Chunxia Chen1, Siyue Li1, Xiaojun Lu1, Bin Tan1, Chunyan Huang1, Li Qin1.   

Abstract

Single nucleotide polymorphisms (SNPs) of VKORC (1173T/C, rs9934438) and CYP2C9 (1075A/C, rs1057910) are major contributory factors on the sensitivity of warfarin in Chinese. Analysis of the two genomic loci could help warfarin treatment individual from bleeding or thrombosis events. An assay with the advantages of simplicity, speed, high sensitivity and low cost for genotyping is calling for clinical laboratories. High resolution method (HRM) meets these callings, but no study with large sample tested its performance in genotyping of rs9934438 and rs1057910. In this study, we identified polymorphisms of rs9934438 and rs1057910 in 255 unrelated Chinese heart valve replacement patients of Han ethnic group from West China Hospital. The two genomic loci were genotyped by HRM using LightCycler® 480 High Resolution Melting Master on LightCycler® 480 Real-Time PCR instruments (Roche Diagnostics), and all amplified PCR products were sent for direct DNA sequencing. The genotyping of rs1057910 between HRM and sequencing showed perfect 100% concordance. While the concordance of rs9934438 between HRM and sequencing was 99.2%. Unexpected mutation interfered genotyping results of HRM when genotyping rs9934438. HRM is a valuable technique for genotype detection of rs9934438 and rs1057910 to assess individual sensitivity to warfarin, where DNA sequencing is added inevitably sometimes.

Entities:  

Keywords:  CYP2C9; HRM; VKORC; genotyping; warfarin

Mesh:

Substances:

Year:  2014        PMID: 24966969      PMCID: PMC4069951     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  Pathology consultation on warfarin pharmacogenetic testing.

Authors:  Gary Stack
Journal:  Am J Clin Pathol       Date:  2011-01       Impact factor: 2.493

2.  Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner.

Authors:  Nienke van der Stoep; Chantal D M van Paridon; Tom Janssens; Petra Krenkova; Alexandra Stambergova; Milan Macek; Gert Matthijs; Egbert Bakker
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

3.  Assessing high-resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments.

Authors:  Elizabeth A Tindall; Desiree C Petersen; Paula Woodbridge; Katharina Schipany; Vanessa M Hayes
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

4.  Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

Authors:  Amanda R Patrick; Jerry Avorn; Niteesh K Choudhry
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-07-21

5.  Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.

Authors:  Mattias Wieloch; Anders Själander; Viveka Frykman; Mårten Rosenqvist; Niclas Eriksson; Peter J Svensson
Journal:  Eur Heart J       Date:  2011-05-26       Impact factor: 29.983

6.  Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.

Authors:  Joyce H S You; Raymond S M Wong; Mary M Y Waye; Yawei Mu; Cadmon K Lim; Kai-Chow Choi; Gregory Cheng
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

7.  [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].

Authors:  Yue Huang; Jing-Fang Yang; Xiao-Lian Qi; Yu-Qin Wang; Wei-Zhi Wang; Biao Chen
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-10-17

8.  Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

Authors:  Tohru Aomori; Koujirou Yamamoto; Atsuko Oguchi-Katayama; Yuki Kawai; Takefumi Ishidao; Yasumasa Mitani; Yasushi Kogo; Alexander Lezhava; Yukiyoshi Fujita; Kyoko Obayashi; Katsunori Nakamura; Hugo Kohnke; Mia Wadelius; Lena Ekström; Cristine Skogastierna; Anders Rane; Masahiko Kurabayashi; Masami Murakami; Paul E Cizdziel; Yoshihide Hayashizaki; Ryuya Horiuchi
Journal:  Clin Chem       Date:  2009-01-30       Impact factor: 8.327

9.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more
  4 in total

1.  Prothrombin C20209T mutation in deep vein thrombosis: a case report.

Authors:  Mariela Muñoz; Cristian Vilos; Mario Cantín
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers.

Authors:  Zahra Ghasemi; Mehrdad Hashemi; Mahsa Ejabati; Seyyed Meisam Ebrahimi; Hamidreza Kheiri Manjili; Ali Sharafi; Ali Ramazani
Journal:  Avicenna J Med Biotechnol       Date:  2016 Oct-Dec

Review 3.  ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Authors:  Yan Jiang; Chen-Yang Zhao; Li-Chun Cheng; Bing Xu; Hui-Yi Lv
Journal:  Hered Cancer Clin Pract       Date:  2017-06-13       Impact factor: 2.857

Review 4.  Technologies for Pharmacogenomics: A Review.

Authors:  Maaike van der Lee; Marjolein Kriek; Henk-Jan Guchelaar; Jesse J Swen
Journal:  Genes (Basel)       Date:  2020-12-04       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.